Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1984 1
1985 3
1986 2
1990 1
1992 1
1995 4
2000 1
2002 1
2007 4
2008 4
2009 3
2010 5
2011 2
2012 1
2013 3
2014 3
2016 2
2017 1
2019 6
2020 4
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Effects of intensive glucose lowering in type 2 diabetes.
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Action to Control Cardiovascular Risk in Diabetes Study Group, et al. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6. N Engl J Med. 2008. PMID: 18539917 Free PMC article. Clinical Trial.
Effects of combination lipid therapy in type 2 diabetes mellitus.
ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. ACCORD Study Group, et al. N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228404 Free PMC article. Clinical Trial.
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. ACCORD Study Group, et al. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228401 Free PMC article. Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Dr. Tibaldi, et al reply.
Tibaldi J, Saccomanno B, Caorsi R, Ravelli A. Tibaldi J, et al. J Rheumatol. 2019 Oct;46(10):1424. doi: 10.3899/jrheum.190551. Epub 2019 Jun 15. J Rheumatol. 2019. PMID: 31203230 No abstract available.
Recent therapeutic advances in juvenile idiopathic arthritis.
Giancane G, Alongi A, Rosina S, Tibaldi J, Consolaro A, Ravelli A. Giancane G, et al. Among authors: tibaldi j. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):476-487. doi: 10.1016/j.berh.2018.01.001. Epub 2018 Feb 26. Best Pract Res Clin Rheumatol. 2017. PMID: 29773268 Review.
Evolution of insulin: from human to analog.
Tibaldi JM. Tibaldi JM. Am J Med. 2014 Oct;127(10 Suppl):S25-38. doi: 10.1016/j.amjmed.2014.07.005. Am J Med. 2014. PMID: 25282010 Review.
Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus.
Rosina S, Tibaldi J, Mazzoni M, Bava C, Natoli V, Ravelli A. Rosina S, et al. Among authors: tibaldi j. Arthritis Care Res (Hoboken). 2020 Oct;72 Suppl 10:163-170. doi: 10.1002/acr.24212. Arthritis Care Res (Hoboken). 2020. PMID: 33091272 Review. No abstract available.
58 results